Singapore markets close in 3 hours 9 minutes
Straits Times Index
3,279.22 -13.91 (-0.42%) Nikkei
37,634.56 -825.52 (-2.15%) Hang Seng
17,270.49 +69.22 (+0.40%) FTSE 100
8,040.38 -4.43 (-0.06%) Bitcoin USD
64,325.23 -2,387.41 (-3.58%) CMC Crypto 200
1,387.90 -36.20 (-2.54%)
Viking Therapeutics, Inc. (VKTX)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 64.93 |
| Open | 65.70 |
| Bid | 64.98 x 400 |
| Ask | 65.13 x 400 |
| Day's range | 64.43 - 67.78 |
| 52-week range | 8.28 - 99.41 |
| Volume | |
| Avg. volume | 6,456,151 |
| Market cap | 7.172B |
| Beta (5Y monthly) | 1.10 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.91 |
| Earnings date | 24 Jul 2024 - 29 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 113.80 |
- GuruFocus.com
Viking Therapeutics Reports First Quarter 2024 Results: Aligns with Analyst Projections
Key Financial and Clinical Highlights from Viking Therapeutics' Recent Earnings Report
PR NewswireViking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended March 31, 2024, and provided an update on its clinical pipeline and other corporate developments.
- Zacks
Brian Big Idea On Technical Analysis
A look at three stocks where technical analysis can help and the TAZR service.
© 2024 Yahoo. All rights reserved.